Receptor mediated delivery systems for cancer therapeutics

Fundamentals and Applications of Controlled Release Drug Delivery

Volumn , Issue , 2012, Pages 329-355

  Minko, Tamara ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CELLS; CONTROLLED DRUG DELIVERY; DISEASES; DRUG INTERACTIONS; HYALURONIC ACID; MOLECULAR BIOLOGY; TISSUE;

ADVERSE SIDE EFFECTS; ANTI-CANCER AGENTS; CANCER THERAPEUTICS; DELIVERY SYSTEMS; LUTEINIZING HORMONE RELEASING HORMONES; RECEPTOR-MEDIATED ENDOCYTOSIS; RESISTANCE MECHANISMS; TARGETED DELIVERY;

TARGETED DRUG DELIVERY;

EID: 84885121162     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-0881-9_12     Document Type: Chapter

References (97)

1. Ehrlich P (1906) Studies in immunity. Plenium Press, New York
2. Minko T, Dharap SS, Pakunlu RI, Wang Y (2004) Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 5(4):389-406
3. Vyas SP, Singh A, Sihorkar V (2001) Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. Crit Rev Ther Drug Carrier Syst 18(1):1-76
4. Minko T (2004) Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Deliv Rev 56(4):491-509
5. De Paoli P (2008) Novel virally targeted therapies of EBV-associated tumors. Curr Cancer Drug Targets 8(7):591-596
6. Kuo WT, Huang HY, Huang YY (2009) Intracellular trafficking, metabolism and toxicity of current gene carriers. Curr Drug Metab 10(8):885-894
7. Roy P, Noad R (2009) Virus-like particles as a vaccine delivery system: myths and facts. Adv Exp Med Biol 655:145-158
8. Pakunlu RI, Cook TJ, Minko T (2003) Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm Res 20(3):351-359
9. Pakunlu RI, Wang Y, Tsao W, Pozharov V, Cook TJ, Minko T (2004) Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res 64 (17):6214-6224
10. Szakacs G, Jakab K, Antal F, Sarkadi B (1998) Diagnostics of multidrug resistance in cancer. Pathol Oncol Res 4(4):251-257
11. Minko T, Kopeckova P, Kopecek J (1999) Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm Res 16 (7):986-996
12. Harashima H, Shinohara Y, Kiwada H (2001) Intracellular control of gene trafficking using liposomes as drug carriers. Eur J Pharm Sci 13(1):85-89
13. Luzio JP, Parkinson MD, Gray SR, Bright NA (2009) The delivery of endocytosed cargo to lysosomes. Biochem Soc Trans 37(Pt 5):1019-1021
14. Sorkin A, Von Zastrow M (2002) Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 3(8):600-614
15. Torchilin VP (2006) Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 8:343-375
16. Torchilin VP, Khaw BA, Weissig V (2002) Intracellular targets for DNA delivery: nuclei and mitochondria. Somat Cell Mol Genet 27(1-6):49-64
17. Beh CW, Seow WY, Wang Y, Zhang Y, Ong ZY, Ee PL, Yang YY (2009) Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug. Biomacromolecules 10(1):41-48
18. Cuchelkar V, Kopeckova P, Kopecek J (2008) Synthesis and biological evaluation of disulfide- linked HPMA copolymer-mesochlorin e6 conjugates. Macromol Biosci 8(5):375-383
19. Banerjee SS, Chen DH (2008) Multifunctional pH-sensitive magnetic nanoparticles for simultaneous imaging, sensing and targeted intracellular anticancer drug delivery. Nanotechnology 19(50):505104
20. Kale AA, Torchilin VP (2010) Environment-responsive multifunctional liposomes. Methods Mol Biol 605:213-242
21. Kasuya Y, Lu ZR, Kopeckova P, Minko T, Tabibi SE, Kopecek J (2001) Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates. J Control Release 74(1-3):203-211
22. Kasuya Y, Lu ZR, Kopeckova P, Tabibi SE, Kopecek J (2002) Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates. Pharm Res 19(2):115-123
23. Khandare J, Minko T (2006) Polymer-drug conjugates: progress in polymeric prodrugs. Progr PolymSci 31:359-397
24. Minko T, Khandare JJ, Jayant S (2007) Polymeric drugs. In: Matyjaszewski K, Gnanou Y, Leibler L (eds) Macromolecular engineering: from precise macromolecular synthesis to macroscopic material properties and application. WILEY-VCH Verlag GmbH & Co, Weinheim, pp 2541-2595
25. Khandare JJ, Chandna P, Wang Y, Pozharov VP, Minko T (2006) Novel polymeric prodrug with multivalent components for cancer therapy. J Pharmacol Exp Ther 317(3):929-937
26. Pack DW, Hoffman AS, Pun S, Stayton PS (2005) Design and development of polymers for gene delivery. Nat Rev Drug Discov 4(7):581-593
27. Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119(2):243-250
28. Basal E, Eghbali-Fatourechi GZ, Kalli KR, Hartmann LC, Goodman KM, Goode EL, Kamen BA, Low PS, Knutson KL (2009) Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One 4(7):e6292
29. Yuan Y, Nymoen DA, Dong HP, Bjorang O, Shih M, Ie PS, Low CG, Low Trope CG, Davidson B (2009) Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol 40(10):1453-1460
30. Corona G, Giannini F, Fabris M, Toffoli G, Boiocchi M (1998) Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells. Int J Cancer 75(1):125-133
31. Kularatne SA, Low PS (2010) Targeting of nanoparticles: folate receptor. Methods Mol Biol 624:249-265
32. Leamon CP, Low PS (1991) Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA 88(13):5572-5576
33. Xia W, Low PS (2010) Folate-targeted therapies for cancer. J Med Chem 53(19):6811-6824
34. Atkinson SF, Bettinger T, Seymour LW, Behr JP, Ward CM (2001) Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. J Biol Chem 276(30):27930-27935
35. Yoo HS, Park TG (2004) Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release 100(2):247-256
36. Kim YK, Choi JY, Yoo MK, Jiang HL, Arote R, Je YH, Cho MH, Cho CS (2007) Receptor- mediated gene delivery by folate-PEG-baculovirus in vitro. J Biotechnol 131(3):353-361
37. Hwa Kim S, Hoon Jeong J, Chul Cho K, Wan Kim S, Gwan Park T (2005) Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine). J Control Release 104(1):223-232
38. Zheng Y, Song X, Darby M, Liang Y, He L, Cai Z, Chen Q, Bi Y, Yang X, Xu J, Li Y, Sun Y, Lee RJ, Hou S (2009) Preparation and characterization of folate-poly(ethylene glycol)-grafted- trimethylchitosan for intracellular transport of protein through folate receptor-mediated endo- cytosis. J Biotechnol 145(1):47-53
39. Zhang C, Gao S, Jiang W, Lin S, Du F, Li Z, Huang W (2010) Targeted minicircle DNA delivery using folate-poly(ethylene glycol)-polyethylenimine as non-viral carrier. Biomaterials 31(23):6075-6086
40. Biswal BK, Debata NB, Verma RS (2009) Development of a targeted siRNA delivery system using FOL-PEG-PEI conjugate. Mol Biol Rep 37(6):2919-2926
41. Wang H, Zhao P, Liang X, Gong X, Song T, Niu R, Chang J (2010) Folate-PEG coated cationic modified chitosan-cholesterol liposomes for tumor-targeted drug delivery. Biomaterials 31(14):4129-4138
42. Yang L, Li J, Zhou W, Yuan X, Li S (2004) Targeted delivery of antisense oligodeoxynu- cleotides to folate receptor-overexpressing tumor cells. J Control Release 95(2):321-331
43. Zhou W, Yuan X, Wilson A, Yang L, Mokotoff M, Pitt B, Li S (2002) Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. Bioconjug Chem 13(6):1220-1225
44. Lu T, Sun J, Chen X, Zhang P, Jing X (2009) Folate-conjugated micelles and their folate- receptor-mediated endocytosis. Macromol Biosci 9(11):1059-1068
45. Han X, Liu J, Liu M, Xie C, Zhan C, Gu B, Liu Y, Feng L, Lu W (2009) 9-NC-loaded folate- conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro. Int J Pharm 372(1-2):125-131
46. Fan L, Li F, Zhang H, Wang Y, Cheng C, Li X, Gu CH, Yang Q, Wu H, Zhang S (2010) Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials 31 (21):5634-5642
47. Kim SH, Jeong JH, Mok H, Lee SH, Kim SW, Park TG (2007) Folate receptor targeted delivery of polyelectrolyte complex micelles prepared from ODN-PEG-folate conjugate and cationic lipids. Biotechnol Prog 23(1):232-237
48. Kang C, Yuan X, Li F, Pu P, Yu S, Shen C, Zhang Z, Zhang Y (2009) Evaluation of folate- PAMAM for the delivery of antisense oligonucleotides to rat C6 glioma cells in vitro and in vivo. J Biomed Mater Res A 93(2):585-594
49. Patri AK, Kukowska-Latallo JF, Baker JR Jr (2005) Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 57(15):2203-2214
50. Zhang C, Zhao L, Dong Y, Zhang X, Lin J, Chen Z (2010) Folate-mediated poly(3- hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery. Eur J Pharm Biopharm 76(1):10-16
51. Dhar S, Liu Z, Thomale J, Dai H, Lippard SJ (2008) Targeted single-wall carbon nanotube- mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc 130 (34):11467-11476
52. Simonson OE, Svahn MG, Tornquist E, Lundin KE, Smith CI (2005) Bioplex technology: novel synthetic gene delivery pharmaceutical based on peptides anchored to nucleic acids. Curr Pharm Des 11(28):3671-3680
53. Jayant S, Khandare JJ, Wang Y, Singh AP, Vorsa N, Minko T (2007) Targeted sialic acid- doxorubicin prodrugs for intracellular delivery and cancer treatment. Pharm Res 24 (11):2120-2130
54. Oishi M, Nagatsugi F, Sasaki S, Nagasaki Y, Kataoka K (2005) Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages. Chembiochem 6(4):718-725
55. Wakebayashi D, Nishiyama N, Yamasaki Y, Itaka K, Kanayama N, Harada A, Nagasaki Y, Kataoka K (2004) Lactose-conjugated polyion complex micelles incorporating plasmid DNA as a targetable gene vector system: their preparation and gene transfecting efficiency against cultured HepG2 cells. J Control Release 95(3):653-664
56. Cho CS, Cho KY, Park IK, Kim SH, Sasagawa T, Uchiyama M, Akaike T (2001) Receptor- mediated delivery of all trans-retinoic acid to hepatocyte using poly(L-lactic acid) nanoparticles coated with galactose-carrying polystyrene. J Control Release 77(1-2):7-15
57. Wang YC, Liu XQ, Sun TM, Xiong MH, Wang J (2008) Functionalized micelles from block copolymer of polyphosphoester and poly(epsilon-caprolactone) for receptor-mediated drug delivery. J Control Release 128(1):32-40
58. Frungillo L, Martins D, Teixeira S, Anazetti MC, Melo Pda S, Duran N (2009) Targeted antitumoral dehydrocrotonin nanoparticles with L-ascorbic acid 6-stearate. J Pharm Sci 98 (12):4796-4807
59. Luo Y, Bernshaw NJ, Lu ZR, Kopecek J, Prestwich GD (2002) Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm Res 19(4):396-402
60. Jiang G, Park K, Kim J, Kim KS, Oh EJ, Kang H, Han SE, Oh YK, Park TG, Kwang Hahn S (2008) Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA. Biopolymers 89(7):635-642
61. Wulbrand U, Feldman M, Pfestroff A, Fehman HC, Du J, Hiltunen J, Marquez M, Arnold R, Westlin JE, Nilsson S, Holmberg AR (2002) A novel somatostatin conjugate with a high affinity to all five somatostatin receptor subtypes. Cancer 94(4 Suppl):1293-1297
62. Zhang J, Jin W, Wang X, Wang J, Zhang X, Zhang Q (2010) A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol Pharm 7(4):1159-1168
63. Rosenzweig SA, Atreya HS (2010) Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol 80(8):1115-1124
64. Laursen LS, Kjaer-Sorensen K, Andersen MH, Oxvig C (2007) Regulation of insulin-like growth factor (IGF) bioactivity by sequential proteolytic cleavage of IGF binding protein-4 and -5. Mol Endocrinol 21(5):1246-1257
65. Magadala P, Amiji M (2008) Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J 10(4):565-576
66. Qiu Q, Domarkas J, Banerjee R, Katsoulas A, McNamee JP, Jean-Claude BJ (2007) Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05. Anticancer Drugs 18(2):171-177
67. Dai FH, Chen Y, Ren CC, Li JJ, Yao M, Han JS, Gong Y, Yang SL, Zhu JD, Gu JR (2003) Construction of an EGF receptor-mediated histone H1(0)-based gene delivery system. J Cancer Res Clin Oncol 129(8):456-462
68. Kickhoefer VA, Han M, Raval-Fernandes S, Poderycki MJ, Moniz RJ, Vaccari D, Silvestry M, Stewart PL, Kelly KA, Rome LH (2009) Targeting vault nanoparticles to specific cell surface receptors. ACS Nano 3(1):27-36
69. Lee H, Kim TH, Park TG (2002) A receptor-mediated gene delivery system using streptavidin and biotin-derivatized, pegylated epidermal growth factor. J Control Release 83(1):109-119
70. Lee TK, Han JS, Fan ST, Liang ZD, Tian PK, Gu JR, Ng IO (2001) Gene delivery using a receptor-mediated gene transfer system targeted to hepatocellular carcinoma cells. Int J Cancer 93(3):393-400
71. Backer MV, Gaynutdinov TI, Gorshkova RJ II, Crouch T, Hu R, Aloise M, Arab KP, Backer JM (2003) Humanized docking system for assembly of targeting drug delivery complexes. J Control Release 89(3):499-511
72. Mai J, Song S, Rui M, Liu D, Ding Q, Peng J, Xu Y (2009) A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells. J Control Release 139(3):174-181
73. Shoji M, Sun A, Kisiel W, Lu YJ, Shim H, McCarey BE, Nichols C, Parker ET, Pohl J, Mosley CA, Alizadeh AR, Liotta DC, Snyder JP (2008) Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor Vila. J Drug Target 16(3):185-197
74. Garanger E, Boturyn D, Dumy P (2007) Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem 7 (5):552-558
75. Oba M, Fukushima S, Kanayama N, Aoyagi K, Nishiyama N, Koyama H, Kataoka K (2007) Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alphavbeta3 and alphavbeta5 integrins. Bioconjug Chem 18 (5):1415-1423
76. Dai W, Yang T, Wang X, Wang J, Zhang X, Zhang Q (2009) PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells. J Drug Target 18(4):254-263
77. Li H, Qian ZM (2002) Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 22(3):225-250
78. Lu Q, Teng GJ, Zhang Y, Niu HZ, Zhu GY, An YL, Yu H, Li GZ, Qiu DH, Wu CG (2008) Enhancement of p53 gene transfer efficiency in hepatic tumor mediated by transferrin receptor through irans-arterial delivery. Cancer Biol Ther 7(2):218-224
79. Jiang YY, Liu C, Hong MH, Zhu SJ, Pei YY (2007) Tumor cell targeting of transferrin-PEG- TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation. Bioconjug Chem 18(1):41-49
80. Hatakeyama H, Akita H, Maruyama K, Suhara T, Harashima H (2004) Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int J Pharm 281(1-2):25-33
81. Eavarone DA, Yu X, Bellamkonda RV (2000) Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J Biomed Mater Res 51(1):10-14
82. Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H (2007) Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm 329(1-2):94-102
83. Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O, Ogiwara N, Johkura K, Yonemura Y (2002) Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 99 (1):130-137
84. Maruyama K, Ishida O, Kasaoka S, Takizawa T, Utoguchi N, Shinohara A, Chiba M, Kobayashi H, Eriguchi M, Yanagie H (2004) Intracellular targeting of sodium mercaptounde- cahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron- capture therapy (BNCT). J Control Release 98(2):195-207
85. Kakudo T, Chaki S, Futaki S, Nakase I, Akaji K, Kawakami T, Maruyama K, Kamiya H, Harashima H (2004) Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 43(19):5618-5628
86. Jhaveri MS, Rait AS, Chung KN, Trepel JB, Chang EH (2004) Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther 3(12):1505-1512
87. Chen S, Zhao X, Chen J, Kuznetsova L, Wong SS, Ojima I (2010) Mechanism-based tumortargeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjug Chem 21(5):979-987
88. Chen J, Chen S, Zhao X, Kuznetsova LV, Wong SS, Ojima I (2008) Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. J Am Chem Soc 130(49):16778-16785
89. Yuan H, Luo K, Lai Y, Pu Y, He B, Wang G, Wu Y, Gu Z (2010) A novel poly(L-glutamic acid) dendrimer based drug delivery system with both pH-sensitive and targeting functions. Mol Pharm 7(4):953-962
90. Chandna P, Saad M, Wang Y, Ber E, Khandare J, Vetcher AA, Soldatenkov VA, Minko T (2007) Targeted proapoptotic anticancer drug delivery system. Mol Pharm 4(5):668-678
91. Dharap SS, Minko T (2003) Targeted proapoptotic LHRH-BH3 peptide. Pharm Res 20 (6):889-896
92. Dharap SS, Qiu B, Williams GC, Sinko P, Stein S, Minko T (2003) Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release 91 (1-2):61-73
93. Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, Sinko PJ, Stein S, Farmanfarmaian A, Minko T (2005) Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci USA 102(36):12962-12967
94. Minko T, Patil ML, Zhang M, Khandare JJ, Saad M, Chandna P, Taratula O (2010) LHRH- targeted nanoparticles for cancer therapeutics. Methods Mol Biol 624:281-294
95. Saad M, Garbuzenko OB, Ber E, Chandna P, Khandare JJ, Pozharov VP, Minko T (2008) Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release 130(2):107-114
96. Taratula O, Garbuzenko OB, Kirkpatrick P, Pandya I, Savla R, Pozharov VP, He H, Minko T (2009) Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release 140(3):284-293
97. Conn PM, Hazum E (1981) Luteinizing hormone release and gonadotropin-releasing hormone (GnRH) receptor internalization: independent actions of GnRH. Endocrinology 109 (6):2040-2045